APG101

DRUG2 trials

Sponsors

Apogenix GmbH, University Hospital Heidelberg

Conditions

Glioblastoma MultiformeGlioblastoma, Adult

Phase 1

NCT Neuro Master Match - N²M² (NOA-20)

CompletedNCT03158389

University Hospital HeidelbergGlioblastoma, Adult

Start: 2018-05-07End: 2023-02-22Updated: 2023-09-28

Phase 2

APG101 in Glioblastoma

CompletedNCT01071837

Apogenix GmbHGlioblastoma Multiforme

Start: 2009-12-31End: 2014-10-31Updated: 2015-06-16

Related Papers

Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N2M2 umbrella trial

Nature Medicine2025-09-054 citations

Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trial.

2024-10-241 citations

N2M2/NOA-20: Phase I/IIa umbrella trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without <i>MGMT</i> promoter hypermethylation.

Journal of Clinical Oncology2024-06-011 citations

Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system

Neuro-Oncology Advances2023-01-0117 citations

P14.52 Differential methylation of a single CpG site in the CD95 ligand promoter affects gene activity and correlates with invasiveness of glioma cells

Neuro-Oncology2019-08-01

Longitudinal analysis of quality of life following treatment with asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients.

Journal of Clinical Oncology2019-05-202 citations

ATIM-13. ASUNERCEPT PLUS RADIOTHERAPY IN RELAPSED GLIOBLASTOMA. UPDATE ON FIVE YEARS OVERALL SURVIVAL OF STUDY NCT01071837 AND DEVELOPMENT OF A POPULATION-PK - TUMOR GROWTH INHIBITION - SURVIVAL MODEL

Neuro-Oncology2018-11-011 citations

Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma

Molecular Cancer Research2018-02-1634 citations

Abstract A115: The CD95 ligand inhibitor APG 101 reduces tumor recurrence and metastasis in an adjuvant orthotopic mouse model of pancreatic cancer as well as primary tumor load in a palliative setting

Cancer Research2015-06-301 citations

Final results of APG101_CD_002: APG101 plus reirradiation versus reirradiation in the treatment of patients with progressive glioblastoma.

Journal of Clinical Oncology2014-05-202 citations